Loading…
Loading…
GERM (ETFMG Treatments, Testing and Advancements ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund invests at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Is GERM's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
CHICAGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Amplify ETFs, a leading provider of exchange traded funds, today announced the scheduled liquidation of three ETFs (the “Funds”). The Funds scheduled for liquidation include: ETF Name Ticker Amplify Emerging Markets FinTech ETF EMFQ Amplify Treatments, Testing and Advancements ETF GERM Amplify Inflation Fighter ETF IWIN Based on the recommendation of Amplify Investments LLC, the Funds' investment adviser, the Board of Trustees of the Amplify ETF Trust unanimously determined that it is in the best interests of the Funds and their shareholders to liquidate the Funds.
Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?
In June, the ETF industry learned that issuer ETF Managers Group would be selling its funds to Amplify ETFs. The transaction, once completed, will bring Amplify's total AUM to $8 billion invested across 29 ETFs.
The week ending Friday, July 21, has been busy for the ETF industry, though launches were muted. A total of seven funds rolled out, which suggests the market could be entering some kind of summer slump.
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.